研究报告Research Report 21 Mar 2024 时代天使 Angelalign (6699 HK) 出海逻辑强化第二增长曲线，差异化产品组合及医学服务优势突出 Overseas Expansion Strengthen the Second Growth Curve, With Outstanding Advantages in Differentiated Product Portfolio and Medical Services [观Ta点ble聚_y焦em Ieniv1e]s tment Focus [Tab维le_持Info优] 于大市Maintain OUTPERFORM (Please see APPENDIX 1 for English summary) 事件：公司发布2023年年报 评级 优于大市OUTPERFORM 现价 HK$75.10 第二增长曲线兑现，国际业务加速。2023年公司实现隐形矫治案例总 目标价 HK$103.50 数约 24.50万例（+33%），其中国内 21.20万例（+15%），国际 3.30 万例，国际案例占总案例数达 13%。公司已经搭建起覆盖欧 ...

智通财经APP获悉，时代天使(06699)涨幅扩大逾18%，高见77.4港元创去年7月底以来新高。截至发 稿，涨17.2%，报76.3港元，成交额1.66亿港元。 消息面上，时代天使发布2023年度业绩，该集团取得收入人民币14.76亿元(单位下同)，同比增加 16.24%；公司拥有人应占利润5347.5万元；每股盈利0.32元，拟派发特别末期股息每股1.1港元。期内集 团国内业务保持稳健增长，而国际业务快速发展。整体隐形矫治达成案例数从约18.39万例同比增长 33.2%至约24.5万例。 此外，时代天使昨日宣布，以零代价自合伙企业收购CC Orthodontics所有股权公告，合伙企业旨在投资 全球数字化正畸价值链中的创新数字化技术及产品。CC Orthodontics为合伙企业为投资其投资组合公司 而成立的投资控股公司。截至该公告日期，其已投资全球数字化正畸产业链上的数家公司。 ...

证券研究报告·海外公司点评·医疗保健设备和服务(HS) 时代天使（06699.HK） 2023 年年报点评：全球案例数达 24.5 万例， 2024年 03月 20日 海外表现亮眼 证券分析师 朱国广 买入（维持） 执业证书：S0600520070004 zhugg@dwzq.com.cn [Table_EPS] 盈利预测与估值 2022A 2023A 2024E 2025E 2026E 股价走势 营业总收入（百万元） 1,273 1,476 1,770 2,050 2,431 同比 -0.10% 15.98% 19.89% 15.87% 18.54% 时代天使 恒生指数 13% 归母净利润（百万元） 213.78 53.48 78.43 119.91 163.90 6% -1% 同比 -25.21% -74.99% 46.66% 52.90% 36.68% -8% -15% -22% EPS-最新摊薄（元/股） 1.26 0.32 0.46 0.71 0.97 -29% -36% P/E（现价&最新摊薄） 51.49 205.86 140.37 91.80 67.16 --- 554 703 %%% [ [ ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 ANGELALIGN TECHNOLOGY INC. 時代天使科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6699） 截至2023年12月31日止年度的年度業績公告 時代天使科技有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事（「董 事」）會（「董事會」）欣然公佈本集團截至2023年12月31日止年度（「報告期間」）的 經審核綜合年度業績，連同截至2022年12月31日止年度的比較數字，有關業績已 經由本公司審核委員會（「審核委員會」）審閱。 於本公告中，「我們」、「我們的」及「時代天使」指本公司及（除非文義另有規定） 本集團。除文義另有所指外，本公告所用詞彙與日期為2021年6月3日的本公司招 股章程（「招股章程」）所界定者具有相同涵義。 業績概要 | --- | --- | |-------|------------------------------------------ ...

angelalign angelalign angelalign angelalign angelalign angelalign angelalign angelalign angelalign angelalign a n gelalig n a ngelalign angelalign angelalign angelalign a ngelalign angelalign angelalign angelalign angelalign ange al l gi n ange al l gi n ange al l gi n a n ge al l gi n a n gelalign a ngelalign angelalign angelalign a n ge al l gi n a n g elalig n a n gelalign a ngelalign angelalign ange al l gi n ange al l gi n a n g e al lig n a ngelalign angelalign ange al l gi n angelalig n a n gelalign ...

Financial Performance - For the six months ended June 30, 2023, the total number of cases achieved in domestic and international markets increased by 23.6% year-on-year to approximately 95,400 cases, compared to 77,200 cases for the same period in 2022[3]. - Revenue for the six months ended June 30, 2023, rose to approximately RMB 616.3 million, up from RMB 570.9 million for the same period in 2022, primarily due to stable growth in domestic invisible orthodontic solutions and continued investment in international business[3]. - Gross profit for the six months ended June 30, 2023, increased to approximately RMB 365.7 million, compared to RMB 331.4 million for the same period in 2022[3]. - The gross profit margin for the six months ended June 30, 2023, was 59.3%, up from 58.0% for the same period in 2022, with the domestic invisible orthodontic solutions gross profit margin at 61.7% compared to 60.2% in the previous year[3]. - Net profit for the six months ended June 30, 2023, decreased to approximately RMB 29.3 million, down from RMB 73.3 million for the same period in 2022, mainly due to initial investments in international business[3]. - Adjusted EBITDA for the six months ended June 30, 2023, was approximately RMB 45.3 million, down from RMB 111.9 million for the same period in 2022[3]. - The total comprehensive income for the six months ended June 30, 2023, was RMB 130.3 million, compared to RMB 196.8 million for the same period in 2022[6]. - Total revenue for the six months ended June 30, 2023, was RMB 661,469,000, an increase from RMB 526,594,000 in the same period of 2022, representing a growth of approximately 25.6%[36]. - The net profit attributable to the company's owners for the six months ended June 30, 2023, was RMB 32,308,000, down from RMB 74,307,000 in the same period of 2022, indicating a decline of about 56.5%[44]. - The company reported a profit of RMB 32,308 thousand for the period, contributing to a total comprehensive income of RMB 128,744 thousand for the six months ended June 30, 2023[9]. Assets and Liabilities - As of June 30, 2023, total assets amounted to RMB 4,688.9 million, compared to RMB 4,486.2 million as of December 31, 2022[7]. - The equity attributable to the owners of the company as of June 30, 2023, was RMB 3,358.9 million, down from RMB 3,606.8 million as of December 31, 2022[7]. - Total liabilities increased to RMB 1,260,238 thousand as of June 30, 2023, compared to RMB 884,012 thousand as of December 31, 2022, representing a growth of 42.5%[8]. - The total equity attributable to owners reached RMB 3,358,866 thousand as of June 30, 2023, up from RMB 3,606,766 thousand at the beginning of the year, indicating a decrease of 6.9%[9]. - The company’s bank borrowings stood at RMB 8,881 thousand as of June 30, 2023, with total current liabilities amounting to RMB 830,697 thousand, an increase from RMB 781,490 thousand at the end of 2022[8]. - The company’s total equity and liabilities amounted to RMB 4,688,895 thousand as of June 30, 2023, compared to RMB 4,486,209 thousand at the end of 2022, indicating an increase of 4.5%[8]. Cash Flow and Financial Position - The net cash used in operating activities was RMB (93,027) thousand for the six months ended June 30, 2023, compared to RMB 31,496 thousand for the same period in 2022, reflecting a significant decline in cash flow[12]. - Cash and cash equivalents decreased by RMB 715,762 thousand, ending at RMB 3,028,317 thousand as of June 30, 2023, compared to RMB 3,519,974 thousand at the end of the previous period[12]. - The company’s cash position reflects a significant liquidity challenge, with a notable decrease in cash reserves compared to the previous year[65]. - The company maintains a net cash position as of June 30, 2023, consistent with the position on December 31, 2022[23]. - The company’s current ratio as of June 30, 2023, was 4.6, slightly down from 5.0 as of December 31, 2022[144]. Expenses and Costs - Employee benefits expenses increased to RMB 327,216,000 for the six months ended June 30, 2023, from RMB 256,761,000 in the same period of 2022, reflecting a rise of approximately 27.4%[36]. - Sales and marketing expenses increased by 59.7% to RMB 204.1 million, primarily due to international business expansion[120]. - Administrative expenses rose by 44.0% to RMB 120.7 million, mainly due to increased costs associated with international operations[121]. - The company incurred a total tax expense of RMB 6,267,000 for the six months ended June 30, 2023, down from RMB 9,260,000 in the same period of 2022, representing a decrease of approximately 32.3%[37]. - The company reported a significant increase in administrative expenses, which rose to RMB 6,595 thousand in the first half of 2023 from RMB 649 thousand in the same period of 2022[52]. Research and Development - The company achieved a research and development expenditure of RMB 86.1 million, accounting for 14.0% of its revenue as of June 30, 2023[104]. - R&D expenses increased by 14.2% to RMB 86.1 million, driven by professional and consulting fees related to ongoing R&D efforts[122]. - The company launched the angelLink system in June 2023, which is the first clear aligner mechanical interface designed to address clinical challenges in complex malocclusion cases[100]. - The company upgraded its digital remote diagnosis solution, MOOELI, was released in the first half of the year, improving diagnostic quality and patient interaction[103]. - The company established a strategic global partnership with 3Shape A/S for digital intraoral scanning, facilitating seamless data upload to its cloud service platform[102]. Market and Business Strategy - The company is focused on managing liquidity risk by monitoring cash reserves and cash flow forecasts[21]. - The company has plans for market expansion and new product development as part of its future strategy[48]. - The company continues to focus on digitalization and internationalization as part of its long-term strategic layout[99]. - The company has successfully established its position in the international market and expects this to drive future business growth[99]. - The company aims to enhance R&D capabilities and continue innovating orthodontic solutions to maintain market leadership[113]. Corporate Governance - The audit committee consists of three independent non-executive directors, with Mr. Zhou Hao serving as the chairman[153]. - The company has adopted the corporate governance code as per the listing rules and confirmed compliance during the review period[151]. - The company emphasizes the importance of high corporate governance standards to protect shareholder interests and enhance transparency[150]. - As of April 2023, the company did not meet certain corporate governance requirements but has since regained compliance following the appointment of Mr. Zhou Hao as an independent non-executive director[153].

2022 2022 （於開曼群島註冊成立之有限公司） 股份代號：6699 年度報告 | --- | --- | |------------------------------------------------------------------------|------------------------------------------------| | | | | ANGELALIGN ANGELALIGN | | | | | | ANGELALIGN ANGELALIGN ANGELALIGN ANGELALIGN | | | ANGELALIGN ANGELALIGN | ANGELALIGN | | ANGELALIGN ANGELALIGN | ANGELALIGN | | ANGELALIGN | | | ANGELALIGN ANGELALIGN ANGELALIGN | 时代天使 | | ANGELALIGN ANGELALIGN ANGELALIGN ANGELALIGN ANGELALIGN ANGELALIGN | | | ANGELALIGN ANGELALIGN ANGELAL ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 ANGELALIGN TECHNOLOGY INC. 時代天使科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6699） 截至2022年12月31日止年度的年度業績公告 時代天使科技有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事（「董 事」）會（「董事會」）欣然公佈本集團截至2022年12月31日止年度（「報告期間」）的 經審核綜合年度業績，連同截至2021年12月31日止年度的比較數字，有關業績已 經由本公司審核委員會（「審核委員會」）審閱。 於本公告中，「我們」、「我們的」及「時代天使」指本公司及（除非文義另有規定） 本集團。除文義另有所指外，本公告所用詞彙與日期為2021年6月3日的本公司招 股章程（「招股章程」）所界定者具有相同涵義。 業績概要 | --- | --- | |-------|------------------------------------------ ...